SZLSF (StageZero Life Sciences) EBIT per Share: $-0.01 (TTM As of Sep. 2024)


SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.01
View Full Analysis

What is StageZero Life Sciences EBIT per Share?

StageZero Life Sciences SZLSF 10 EBIT per Share is $-0.01 as of Sep. 2024. GuruFocus rates SZLSF with a GF Score™ of 10/100.

StageZero Life Sciences's EBIT per Share for the three months ended in Sep. 2024 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for StageZero Life Sciences's EBIT per Share or its related term are showing as below:

SZLSF's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 12.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

StageZero Life Sciences's EBIT for the three months ended in Sep. 2024 was $-0.35 Mil.

StageZero Life Sciences  (OTCPK:SZLSF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

StageZero Life Sciences EBIT per Share Related Terms

StageZero Life Sciences EBIT per Share Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences EBIT per Share Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.18 -0.08 -0.15 -0.10 -0.11

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 -0.00 -0.01 -0.00
SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

StageZero Life Sciences's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBIT per Share(A: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-11.196/99.426
=-0.11

StageZero Life Sciences's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

EBIT per Share(Q: Sep. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.352/123.533
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.01 mean?
StageZero Life Sciences (SZLSF) has a EBIT per Share of $-0.01 as of Sep. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' EBIT per Share too high?
StageZero Life Sciences' current EBIT per Share is $-0.01. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' EBIT per Share compare to IDTA and TTOO?
StageZero Life Sciences' EBIT per Share of $-0.01 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on StageZero Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StageZero Life Sciences's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current EBIT per Share of $-0.01. The current EBIT per Share is $-0.01. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current EBIT per Share is $-0.01 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price